Curis (CRIS) closed at $0.40 on October 20, 2026, up 4.6% from the previous close, on volume of 211,410 shares (30-day average 225,098).
Data as of October 20, 2026.
Curis Secures PIPE Financing Through Securities Purchase Agreement
TipRanks (Mon, 19-Oct 5:02 PM ET)
Curis prices $8.5M private placement offering
Seeking Alpha News (Fri, 16-Oct 8:31 AM ET)
PRNewswire (Fri, 16-Oct 8:00 AM ET)
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
PRNewswire (Thu, 13-Aug 8:00 AM ET)
Curis Doses First Five Patients in TakeAim CLL Study
PRNewswire (Thu, 30-Jul 8:01 AM ET)
Market Chameleon (Wed, 22-Jul 4:12 AM ET)
Curis Announces Positive Emavusertib Update
PRNewswire (Wed, 22-Jul 7:00 AM ET)
Market Chameleon (Fri, 26-Jun 7:48 AM ET)
Market Chameleon (Thu, 8-Jan 6:56 AM ET)
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis trades on the NASDAQ stock market under the symbol CRIS.
As of October 21, 2026, CRIS stock price declined to $0.39 with 80,168 million shares trading.
CRIS has a beta of 5.35, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.05 to the broad based SPY ETF.
CRIS has a market cap of $945,780.00. This is considered a Sub-Micro Cap stock.
Last quarter Curis reported $0 in Revenue and -$4.02 earnings per share. This fell short of revenue expectation by $-750,000 and exceeded earnings estimates by $1.29.
In the last 3 years, CRIS traded as high as $17.49 and as low as $.18.
The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VXF.
CRIS has underperformed the market in the last year with a price return of -75.3% while the SPY ETF gained +16.4%. CRIS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -91.4% and -47.9%, respectively, while the SPY returned +4.5% and -0.7%, respectively.
CRIS support price is $.37 and resistance is $.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.
